1. Home
  2. AMRC vs ZYME Comparison

AMRC vs ZYME Comparison

Compare AMRC & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ameresco Inc.

AMRC

Ameresco Inc.

HOLD

Current Price

$30.67

Market Cap

1.8B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$26.43

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AMRC
ZYME
Founded
2000
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
2.0B
IPO Year
2010
2017

Fundamental Metrics

Financial Performance
Metric
AMRC
ZYME
Price
$30.67
$26.43
Analyst Decision
Buy
Strong Buy
Analyst Count
9
9
Target Price
$33.22
$32.75
AVG Volume (30 Days)
468.7K
589.6K
Earning Date
11-03-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
18.87
N/A
EPS
1.19
N/A
Revenue
$1,883,767,000.00
$134,481,000.00
Revenue This Year
$9.83
$63.57
Revenue Next Year
$9.83
$89.45
P/E Ratio
$24.61
N/A
Revenue Growth
12.22
116.21
52 Week Low
$8.49
$9.03
52 Week High
$44.93
$28.49

Technical Indicators

Market Signals
Indicator
AMRC
ZYME
Relative Strength Index (RSI) 46.11 57.49
Support Level $28.72 $26.10
Resistance Level $30.90 $26.91
Average True Range (ATR) 1.24 0.95
MACD 0.13 -0.25
Stochastic Oscillator 58.50 49.84

Price Performance

Historical Comparison
AMRC
ZYME

About AMRC Ameresco Inc.

Ameresco Inc provides energy efficiency solutions for facilities in North America and Europe. It focuses on projects that reduce energy, also focuses on the operations and maintenance costs of governmental, educational, utility, healthcare, and other institutional, commercial, and industrial entities facilities. Ameresco distributes solar energy products and systems, such as PV panels, solar regulators, solar charge controllers, inverters, solar-powered lighting systems, solar-powered water pumps, solar panel mounting hardware, and other system components. The company's segment includes U.S. Regions; U.S. Federal; Canada; Alternative Fuels; Non-Solar DG and All Other. It derives a majority of its revenue from the U.S. Regions segment.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: